HF
KERX

HRT Financial’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

HRT Financial’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-15,299
Closed -$152K – 213
2015
Q2 		$152K Buy
+15,299
New +$164K 0.07% 132

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

HRT Financial's KERX Position: Q3 2015 in Review

HRT Financial sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2015, closing a stake of 15,299 shares — an estimated $152K sold.

HRT Financial first reported a position in KERX in Q2 2015 and held it in 1 quarter. The position peaked at $152K in Q2 2015. 138 funds tracked by Wall St. Rank hold KERX as of Q3 2015.

  • HRT Financial reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2015 after selling out during the quarter.
  • HRT Financial sold 15,299 Keryx Biopharmaceuticals Inc shares in Q3 2015, an estimated $152K.
  • HRT Financial first reported a position in Keryx Biopharmaceuticals Inc in Q2 2015 and held it in 1 quarter.
  • HRT Financial's Keryx Biopharmaceuticals Inc position peaked at $152K in Q2 2015.
  • 138 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2015.

Based on HRT Financial's 13F filing for Q3 2015, filed 12 Nov 2015.